Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01659827 · ClinicalTrials.gov registry record · NA

Comparative Study of Amniotic Membrane Injectable in the Treatment of Recalcitrant Plantar Fasciitis

A NA study of Plantar Fasciitis, sponsored by MiMedx Group.

Completed
Registry status
NA
Development phase
45
Enrollment target
2
Study locations

NCT01659827 is a NA study of Plantar Fasciitis that has completed, run by MiMedx Group. The registered enrollment target is 45 participants, below the 102-participant average among 6 other Plantar Fasciitis trials with a reported enrollment target (56% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01659827, a NA study of Plantar Fasciitis, has completed, sponsored by MiMedx Group.

COMPLETED
Registry status
NA
Development phase
45 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine whether the AmnioFix Injectable human amniotic membrane is effective in the treatment of recalcitrant plantar fasciitis.

Conditions Studied

Interventions

  • OTHER Saline
  • OTHER Marcaine
  • OTHER 0.5cc AmnioFix
  • OTHER 1.25cc AmnioFix

Study Locations (2)

Virginia

  • Professional Education and Research Institute - Roanoke
  • Professional Education and Research Institute - Salem

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2012-09
Est. Completion 2013-03
Phase NA

Sponsor

MiMedx Group

32 total trials

What the Registry Record Tells You About NCT01659827

The ClinicalTrials.gov registry entry for NCT01659827 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 102-participant average among 6 other Plantar Fasciitis trials with a reported enrollment target (56% lower). The listed sponsor is MiMedx Group, which has 32 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Plantar Fasciitis appearing as the primary indexed condition, and to 4 interventions - of which Saline is the first listed.

NCT01659827 reports 2 study locations spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT01659827 about?

NCT01659827 is a clinical study titled "Comparative Study of Amniotic Membrane Injectable in the Treatment of Recalcitrant Plantar Fasciitis". The purpose of this study is to determine whether the AmnioFix Injectable human amniotic membrane is effective in the treatment of recalcitrant plantar fasciitis.

What is the current status of trial NCT01659827?

This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2012-09. Estimated completion is 2013-03.

What conditions does trial NCT01659827 study?

This clinical trial studies the following conditions: Plantar Fasciitis.

What interventions are being tested in trial NCT01659827?

The interventions under investigation include: Saline (OTHER), Marcaine (OTHER), 0.5cc AmnioFix (OTHER), 1.25cc AmnioFix (OTHER).

Who is sponsoring clinical trial NCT01659827?

This trial is sponsored by MiMedx Group, which has 32 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01659827 being conducted?

This trial has 2 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Plantar Fasciitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.